Copenhagen, Denmark

Daniel C Jeffares

This inventor holds 1 USPTO granted patent. Top assignee: Exiqon A/s. Active years: 2016.


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Daniel C Jeffares

Introduction

Daniel C Jeffares is a notable inventor based in Copenhagen, Denmark. He has made significant contributions to the field of molecular biology, particularly in the detection and analysis of nucleic acids. His work has implications for understanding various diseases, including cancer.

Latest Patents

Daniel C Jeffares holds a patent for "Oligonucleotides useful for detecting and analyzing nucleic acids of interest." This invention features improved nucleic acids and methods for expression profiling of mRNAs. It also aids in identifying and profiling particular mRNA splice variants, as well as detecting mutations, deletions, or duplications of specific exons or other splice variants. These advancements are crucial for analyzing biological samples or patient samples, especially in the context of diseases such as cancer. He has 1 patent to his name.

Career Highlights

Jeffares is associated with Exiqon A/S, a company that focuses on providing innovative solutions in the field of molecular diagnostics. His work at Exiqon has allowed him to contribute to the development of tools that enhance the understanding of genetic information.

Collaborations

Some of his notable coworkers include Peter Stein Nielsen and Søren Mørk. Their collaborative efforts have further advanced the research and development of nucleic acid technologies.

Conclusion

Daniel C Jeffares is a prominent figure in the field of molecular biology, with a focus on innovations that improve the detection and analysis of nucleic acids. His contributions are vital for advancing medical research and diagnostics.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…